Patent

EQS-News: Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

Retrieved on: 
星期三, 四月 10, 2024
Biotechnology, Patent, Multiple sclerosis, Calcium, Into, Sclerosis, Pharmaceutical industry

The patent was previously granted to the company in Australia, Canada, Indonesia, Japan and Mexico.

Key Points: 
  • The patent was previously granted to the company in Australia, Canada, Indonesia, Japan and Mexico.
  • “Allowance of this key composition-of-matter patent, covering the specific polymorph of vidofludimus calcium, provides another important layer of proprietary intellectual property protection around our lead, late-stage asset,” stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • “A significant part of this patent will also cover the related method of producing material of vidofludimus calcium used in our studies.
  • On top of the patent exclusivity, vidofludimus calcium, as a new chemical entity, should also benefit from regulatory data protection.

EQS-News: Australian Patent Update

Retrieved on: 
星期三, 四月 10, 2024
Government, Exercise, Federal court, Commissioner, Patent, ASX, United States patent law, Disclosure, EGR, FMK

EcoGraf Limited (“EcoGraf” or the “Company”) (ASX: EGR; FSE: FMK; OTCQB: ECGFF) advises that the delegate of the Australian Commissioner of Patents has issued findings in favour of opposition raised to the Company’s Australian patent application, filed on 1 November 2022 and entitled “Method of Producing Purified Graphite”.

Key Points: 
  • EcoGraf Limited (“EcoGraf” or the “Company”) (ASX: EGR; FSE: FMK; OTCQB: ECGFF) advises that the delegate of the Australian Commissioner of Patents has issued findings in favour of opposition raised to the Company’s Australian patent application, filed on 1 November 2022 and entitled “Method of Producing Purified Graphite”.
  • For full details refer:
    EcoGraf is considering its position in relation to the matter, specifically whether or not it intends to file amendments to overcome the deficiencies identified by the delegate in the Company’s Australian patent application and/or whether to exercise its right of appeal to the Federal Court.
  • The US Patent and Trademark Office has confirmed that the Company’s patent application, filed on 1 November 2022, entitled “Method of Producing Purified Graphite” was granted on 18 July 2023 as US Patent 11,702342 (refer ASX announcement US Patent Granted 19 July 2023).
  • The Company’s EcoGraf HFfree™ Australian Product Qualification Facility is being developed with the support of a $2.9m grant provided by the Australian Government under the Critical Minerals Development Program, with commissioning scheduled to commence next month.

EQS-News: Heidelberg Pharma announces financial figures and reports on successful business performance in 2023

Retrieved on: 
星期三, 四月 10, 2024
Malignancy, Spanish mythology, State university system, Patient, Sale, Renal cell carcinoma, Clinical trial, Neoplasm, Therapy, Depreciation, HPHA, USD, Marketing, GLP, Health, Research, ATACS, EPO, Immune system, ADC, BLA, ATAC, Food, Biologics license application, Disease, Magenta, Multiple myeloma, AACR, GCC, Annual report, FDA, Diagnosis, EUR, Supervisory board, Accounting, PET, EDT, Spacecraft, Amanitin, European Patent Convention, Patent, Eli Lilly and Company, Binghamton University, Pharmaceutical industry

Minority interest in Emergence sold: In summer 2023, Heidelberg Pharma sold its minority interest in Emergence Therapeutics AG, Duisburg, Germany, (Emergence).

Key Points: 
  • Minority interest in Emergence sold: In summer 2023, Heidelberg Pharma sold its minority interest in Emergence Therapeutics AG, Duisburg, Germany, (Emergence).
  • As a result, Heidelberg Pharma lost sales revenue in the low single-digit millions for the 2023 financial year.
  • In April 2023, Heidelberg Pharma signed a termination agreement with Magenta under which all licensed ATAC rights and some Magenta patents were assumed by Heidelberg Pharma.
  • The Heidelberg Pharma Group includes two entities, Heidelberg Pharma AG and Heidelberg Pharma Research GmbH.

EQS-News: Epigenomics AG publishes financial results for fiscal year 2023

Retrieved on: 
星期三, 四月 10, 2024
EUR, Supervisory board, AG, Research, Sale, ECX, HGB, Epigenomics AG, Bank statement, News, Investment, Patent, CSO, Commercial code, Lithium

Berlin (Germany), March 14, 2024 – Epigenomics AG (FSE: ECX, the “Company”) today reported financial results (according to HGB) for fiscal year 2023.

Key Points: 
  • Berlin (Germany), March 14, 2024 – Epigenomics AG (FSE: ECX, the “Company”) today reported financial results (according to HGB) for fiscal year 2023.
  • In July 2023, Epigenomics AG entered into an agreement with New Day Diagnostics LLC for the sale of substantially all of its assets, which was approved by the Extraordinary General Meeting in September 2023 and closed in October 2023.
  • Based on the measures taken, Epigenomics AG expects that the available financial resources will be sufficient until 2026.
  • The annual financial statements for the 2023 fiscal year can be found on the Epigenomics website at: https://www.epigenomics.com/news-investors/financial-reports/ .

The Hunt for the Best in Fintech - Leadership, Innovation, AI Technology Shaping Future Growth

Retrieved on: 
星期三, 三月 20, 2024
Machine learning, Consumer, Growth, Klarna, IPhone, AML, ACH, Blockchain, Zettle, Muumuu, CNBC, Statista, Revolut, Research, Stripe, News, Ant Group, CME, Investment, Cloud computing, Fraud, Venmo, Chicago Mercantile Exchange, BSA, Patent, Iconic, Artificial intelligence, Cryptocurrency

Report Ocean says, "The global Fintech market is on an unparalleled growth trajectory, projected to soar at an impressive CAGR of 25.0% from 2022 to 2028.

Key Points: 
  • Report Ocean says, "The global Fintech market is on an unparalleled growth trajectory, projected to soar at an impressive CAGR of 25.0% from 2022 to 2028.
  • "Escalating investments in technology-driven solutions, including Artificial Intelligence (AI), Machine Learning (ML), cloud computing, and blockchain, are propelling the Fintech sector forward."
  • With strong growth on the horizon for Fintech stocks, the Industry is recognizing excellence and innovation in payments and financial technology to showcase the leaders.
  • For investors, industry recognition is another tool for due diligence, but using the company's technology is the best first hand test for defining the winners of the future.

Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%

Retrieved on: 
星期一, 三月 18, 2024
Cloud, Research, SKQ1, Quality control, Weather, NMPA, Therapeutic Goods Administration, Environment, Best, Intelligence, Patent, Patient, Conditional sentence, Ophthalmology, Hospital, POCT, Acquisition, CMC, European Medicines Agency, GMP, City, QMS, Bevacizumab, Chemistry, Yoy, US FDA, Traction, Good, Therapy, Point-of-care testing, VISTA, Pharmaceutical industry

The Group weathered the headwinds and managed to deliver sound performances amidst the challenging trading environment in 2023.

Key Points: 
  • The Group weathered the headwinds and managed to deliver sound performances amidst the challenging trading environment in 2023.
  • As of 31 December 2023, the Group had cash and cash equivalents of approximately HK$509.8 million (2022: approximately HK$543.5 million).
  • Together with the interim dividend of HK$0.045 per ordinary share paid on 13 September 2023, the total dividend for 2023 would be HK$0.09 (2022: HK$0.065) per ordinary share.
  • The Group's turnover is primarily made up of the ophthalmology segment ("Ophthalmology") and surgical (wound care and healing) segment ("Surgical").

Tome Biosciences Announces US Patent Issued for Integrase-Mediated Programmable Genomic Integration

Retrieved on: 
星期二, 四月 9, 2024
MD, MIT, Patent, Composition, PASTE, PGI, DNA, State, United States patent law

WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announces the issuance of US Patent 11,952,571 for “Systems, Methods, and Compositions for Site-Specific Genetic Engineering Using Programmable Addition via Site-Specific Targeting Elements (PASTE)” by the US Patent and Trademark Office.

Key Points: 
  • WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announces the issuance of US Patent 11,952,571 for “Systems, Methods, and Compositions for Site-Specific Genetic Engineering Using Programmable Addition via Site-Specific Targeting Elements (PASTE)” by the US Patent and Trademark Office.
  • This patent further protects Tome’s foundational PGI technology, integrase-mediated PGI (I-PGI), describes a system capable of performing I-PGI in a mammalian cell, and is exclusively licensed to Tome from MIT.
  • “Today’s issuance marks the fourth US patent granted that encompasses our I-PGI technology, strengthening our patent portfolio and broadening our exclusivity,” said Rahul Kakkar, MD, President and Chief Executive Officer of Tome.
  • Together, with US Patent 11,952,571, these patents cover methods and systems relating to the use of a Cas 9 nickase, reverse transcriptase and an integrase to integrate DNA sequences into programmed locations.

Clearmind Medicine CEO Issues Letter to Shareholders

Retrieved on: 
星期二, 四月 9, 2024
Data monitoring committee, Depression, Obesity, Mevalonate pathway, Psychiatry, Dyskinesia, Addiction, Safety, Binge drinking, Data, DSM-IV codes, Research, MEAI, Clinical trial, Johns Hopkins University, Phase, Patent, Therapy, Ministry, FDA, Impulsivity, CTS, IRB, Pharmaceutical industry

Recently, our efforts reached a key inflection point as the Israeli Ministry of Health approved our Phase I/IIa clinical trial for CMND-100 for AUD.

Key Points: 
  • Recently, our efforts reached a key inflection point as the Israeli Ministry of Health approved our Phase I/IIa clinical trial for CMND-100 for AUD.
  • CMND-100, a pioneering MEAI-based (5-methoxy-2-aminoindane) formula, has exhibited encouraging results in pre-clinical studies.
  • Notably, it has shown the ability to disrupt the destructive cycle of binge drinking without inducing hallucinations—a common concern with existing treatments.
  • The journey ahead is filled with potential, and we eagerly anticipate sharing impactful updates with our shareholders."

WizMediBio Signs Contract with the Wisconsin Alumni Research Foundation (WARF) for Botulinum Toxin Strain

Retrieved on: 
星期二, 四月 9, 2024
A1, Beauty, Research, University, GMP, Wisconsin Alumni Research Foundation, Commerce, Patent, Jan Vansina, WARF, FDA, Pharmaceutical industry

The A1 botulinum toxin currently dominates the market and as a novel subtype, A6 presents itself as a challenger.

Key Points: 
  • The A1 botulinum toxin currently dominates the market and as a novel subtype, A6 presents itself as a challenger.
  • Therefore, the future course of the A6 strain as a BOTULINUM TOXIN provides a new opportunity in the botulinum field.
  • The company aims to capture the botulinum toxin market based on maximized utilization of its distribution network and experience.
  • "We will enhance the global market, especially the U.S., with novel botulinum toxin products," said Choi Yong-hoon, the CEO of WizMedi Bio.

LSU Researchers' Nootkatone Studies Could Lead to Prevention of Lyme Disease

Retrieved on: 
星期二, 四月 9, 2024
Ozone, SCI, Innovation, Lyme disease, Biting, Ant, DEET, Tick, Research, Notifiable disease, Nootkatone, Biology, Che, Military personnel, Leg, NSF, Mosquito net, World Health Organization, CDC, Malaria, WHO, Patent, Chemical engineering, Biol, Tree, West Nile virus, FDA, Defense, Deer, LSU, Vaccine

The LSU researchers propose decreasing the cost of the nootkatone synthesis, making any products made with the compound affordable to the general public.

Key Points: 
  • The LSU researchers propose decreasing the cost of the nootkatone synthesis, making any products made with the compound affordable to the general public.
  • “The family of compounds that make up nootkatone is already proven to be both safer and more effective than existing commercial repellents,” principal investigator Dooley said.
  • Years ago, Laine discovered the efficacy of nootkatone as an insect repellent while collaborating with retired LSU AgCenter Entomologist Gregg Henderson in Laine’s lab.
  • Mosquito nets could be covered with it, or they could have cloth ankle bands with nootkatone so ticks can’t crawl up your leg.